🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for BRCA1 Gene Mutation

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384Phase 31 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Ca… An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results NCT05420064NA8 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation NCT05806515Phase 2133 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging MEASUREMENT OF CIRCULATING MUTATION BURDEN NCT06792721n/a1 site📍 Caen Centre Francois Baclesse · Tests: Mutation Burden cfMB analysis Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance NCT07321015Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Fluzoparib Monotherapy Study of How People Make Decisions About Prostate Cancer Risk NCT07197723n/a1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: cheek (buccal) swab, Assessments, optional collection of blood Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer NCT06201234Phase 236 sites📍 Stuttgart📍 Tübingen📍 Winnenden GBG Forschungs GmbH · Tests: Olaparib + Elacestrant, Olaparib TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention NCT04294927NA66 sites📍 Chicago📍 Boston📍 Rochester University Medical Center Nijmegen · Tests: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy The Cancer of the Pancreas Screening-5 CAPS5)Study NCT02000089Phase 39 sites📍 New Haven📍 Baltimore📍 Boston Johns Hopkins University · Tests: Secretin, MRI, Tumor marker gene test with CA19-9 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer NCT06488378Phase 12 sites📍 Boston📍 Rochester Dana-Farber Cancer Institute · Tests: Axatilimab, Olaparib Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519Phase 1, Phase 214 sites📍 Phoenix📍 New Haven📍 Jacksonville 858 Therapeutics, Inc. · Tests: ETX-19477 Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766Phase 23 sites📍 Gifu📍 Okayama📍 Tokyo Okayama University · Tests: Pembrolizumab, Paclitaxel, Carboplatin, Olaparib, Definitive Surgery Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene NCT06817694NA1 site📍 Québec CHU de Quebec-Universite Laval · Tests: Cognitive-behavioral group therapy Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes NCT03396341n/a7 sites📍 Boston📍 Basking Ridge📍 Commack Memorial Sloan Kettering Cancer Center · Tests: Salvia sample, Questionnaires, Buccal swab sample Prostate Cancer Genetic Risk Evaluation and Screening Study NCT05129605n/a1 site📍 Boston Massachusetts General Hospital · Tests: Prostate cancer screening APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation NCT04858334Phase 2456 sites📍 Anchorage📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration Registry of Subjects at Risk of Pancreatic Cancer NCT04095195n/a4 sites📍 Rozzano📍 Peschiera del Garda📍 Milan Associazione Italiana per lo Studio del Pancreas · Tests: MRCP, Endoultrasonography A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer NCT07532434n/a1 site📍 Beijing Peking University Third Hospital Prophylactic Irradiation to the Contralateral Breast for BCAs Patients NCT04960839NA8 sites📍 Jiangxi📍 Shanghai📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Prophylactic contralateral breast irradiation COsegregation of VARiants in Panel of Genes NCT01689584NA62 sites📍 Bastia📍 Saint-Cloud📍 Amiens Institut Curie · Tests: salivary kit Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy NCT06972719NA2 sites📍 Chapel Hill📍 Durham Duke University · Tests: Experimental Arm, SOC Arm Combination Therapy in Cancers With Mutations in DNA Repair Genes NCT05694715Phase 11 site📍 San Francisco University of California, San Francisco · Tests: Niraparib, Irinotecan Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome NCT04431024n/a1 site📍 Bethesda National Cancer Institute (NCI) BRCA Mutation Carriers' Platform a Multicenter Study NCT07253051n/a40 sites📍 Avellino📍 Aviano📍 Bari Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Registration of clinical datas in the platform Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer NCT07436312NA3 sites📍 Avignon📍 Rennes📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: educational workshop on nutrition + additional intervention on UPF tool and how to use it Pancreas Registry and High Risk Registry NCT02775461n/a2 sites📍 New York📍 New York Icahn School of Medicine at Mount Sinai
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy